Matica to work with Germany's Sartorius on viral vector production

Matica Biotechnology, a wholly owned subsidiary of CHA Biotech, signed an agreement with Göttingen, Germany's Sartorius, to cooperate on developing advanced technologies for large-scale viral vector production.

Logo of Matica Biotechnology

Matica Biotechnology, a wholly owned subsidiary of CHA Biotech, signed an agreement with Göttingen, Germany’s Sartorius, to cooperate on developing advanced technologies for large-scale viral vector production.

Under the agreement, Sartorius will offer Matica its single-use bioreactors that can be used in biopharmaceutical manufacturing processes. Single-use bioreactors use plastic containers and plastic bags in the manufacturing process, thus reducing time and cost. Sartorius has the largest market share in world’s single-use bioreactor market, according to Matica.

Using the bioreactors, Matica will develop process analytical technology (PAT) and automation software needed for mass manufacturing viral vector products. PAT, according to U.S. Food and Drug Administration, refers to a system for designing, analyzing and controlling pharmaceutical manufacturing process through the measurements of critical quality and performance attributes of raw and processed materials to ensure the quality of the final product.

The cooperation will help Matica “build a system that can manufacture viral vector products of great quality and reduce the time.”

"We will constantly endeavor to offer clients satisfying services based on the capabilities of manufacturing high-quality pharmaceuticals quickly and reducing errors in the process,” Song Yun-jeong, CEO of Matica Biotechnology, said in a statement Tuesday.

BY SARAH CHEA [chea.sarah@joongang.co.kr]